Current status of immunotherapy for the treatment of lung cancer

Sanjay Murala, Vamsi Alli, Daniel Kreisel, Andrew E. Gelman, Alexander S. Krupnick

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting lung cancer, and discuss limitations of current therapy and future directions of this field.

Original languageEnglish (US)
Pages (from-to)237-244
Number of pages8
JournalJournal of Thoracic Disease
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2010

Fingerprint

Immunotherapy
Lung Neoplasms
Therapeutics
Neoplasms
Passive Immunization
Small Cell Lung Carcinoma
Ovarian Neoplasms
Melanoma
Clinical Trials
Antigens

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Murala, Sanjay ; Alli, Vamsi ; Kreisel, Daniel ; Gelman, Andrew E. ; Krupnick, Alexander S. / Current status of immunotherapy for the treatment of lung cancer. In: Journal of Thoracic Disease. 2010 ; Vol. 2, No. 4. pp. 237-244.
@article{219a83b516c34ba98348e654d463192b,
title = "Current status of immunotherapy for the treatment of lung cancer",
abstract = "Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting lung cancer, and discuss limitations of current therapy and future directions of this field.",
author = "Sanjay Murala and Vamsi Alli and Daniel Kreisel and Gelman, {Andrew E.} and Krupnick, {Alexander S.}",
year = "2010",
month = "12",
day = "1",
doi = "10.3978/j.issn.2072-1439.2010.11.6",
language = "English (US)",
volume = "2",
pages = "237--244",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "4",

}

Current status of immunotherapy for the treatment of lung cancer. / Murala, Sanjay; Alli, Vamsi; Kreisel, Daniel; Gelman, Andrew E.; Krupnick, Alexander S.

In: Journal of Thoracic Disease, Vol. 2, No. 4, 01.12.2010, p. 237-244.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current status of immunotherapy for the treatment of lung cancer

AU - Murala, Sanjay

AU - Alli, Vamsi

AU - Kreisel, Daniel

AU - Gelman, Andrew E.

AU - Krupnick, Alexander S.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting lung cancer, and discuss limitations of current therapy and future directions of this field.

AB - Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting lung cancer, and discuss limitations of current therapy and future directions of this field.

UR - http://www.scopus.com/inward/record.url?scp=84855341896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855341896&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2072-1439.2010.11.6

DO - 10.3978/j.issn.2072-1439.2010.11.6

M3 - Review article

C2 - 22263052

AN - SCOPUS:84855341896

VL - 2

SP - 237

EP - 244

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 4

ER -